Clinical Briefings™: New Frontiers in Alpha-1 Antitrypsin Deficiency – Analyzing Diagnosis and the Efficacy of Available Therapies

Released On
June 30, 2020

Expires On
June 30, 2021

Media Type

Completion Time
60 minutes


Scroll to the Bottom of this Information to Begin this Course

This activity provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grants from Grifols, S.A.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward pulmonologists, primary care physicians, critical care specialists, and other health care providers involved in the management of patients with pulmonary disease.

Program Overview

This online activity is designed to provide a concise and focused overview of the pathophysiology of α1-antitrypsin deficiency (AATD), the clinical presentation and diagnostic evaluation of patients with this condition, and the efficacy and safety of therapies recommended for the management of pulmonary complications. The multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  • Discuss the genotypic and phenotypic variations in AATD
  • Review clinical, laboratory, and genotype testing in the evaluation of patients with AATD
  • Evaluate efficacy and safety of augmentation therapy and pulmonary management in care of patients with AATD


Timothy Craig, DO

Timothy Craig, DO

Professor of Medicine, Pediatrics, and Graduate Studies
Director of Clinical Research, Allergy, Asthma, and Immunology Center
Director, Alpha-1 Foundation Clinical Resource Center
Penn State University
Hershey, PA

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Timothy Craig, DO

  • Grant Research Support: CSL Behring, Takeda Pharmaceutical Co Ltd, Grifols SA
  • Consultant: CSL Behring, Takeda Pharmaceutical Co Ltd, Grifols SA
  • Other: CME Grant Takeda Pharmaceutical Co Ltd.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/ Audio” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.